Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4)
Conditions
Interventions
bb2121
Fludarabine
+2 more
Locations
22
United States
Local Institution - 119
Phoenix, Arizona, United States
Local Institution - 110
Los Angeles, California, United States
Local Institution - 116
San Francisco, California, United States
Local Institution - 106
Denver, Colorado, United States
Local Institution - 101
Jacksonville, Florida, United States
Local Institution - 113
Tampa, Florida, United States
Start Date
May 27, 2020
Primary Completion Date
June 7, 2023
Completion Date
June 7, 2023
Last Updated
August 23, 2023
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions